Enveric signs deal with MindBio [Green Market Rerport]
Tuesday, May 14, 2024 1 min read
Key Takeaway: Enveric Biosciences has entered into a non-binding term sheet to out-license its Novel Psilocin Prodrugs to MindBio Therapeutics. This partnership aims to advance treatments for psychiatric conditions through the use of microdoses of psychedelic medicines. MindBio is recognized for its innovative approach in the biopharma sector.
Price reaction · baseline $146.7 (2024-05-14T18:09:00.000Z) · hit during market hours · 8 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+0.7%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric has secured a partnership with MindBio Therapeutics.
The deal involves innovative treatments for psychiatric conditions.
MindBio is focused on pioneering novel therapies using psychedelics.
Full Press Release Details
Enveric Biosciences, Inc. (NASDAQ: ENVB) told investors it has signed a non-binding term sheet to out-license a class of Novel Psilocin Prodrugs (NPP) to Vancouver, BC-based MindBio Therapeutics (CNSX: MBIO), a clinical-stage biopharma company, which is pioneering novel treatments for psychiatric conditions using microdoses of psychedelic medicines.
Full Article >>
Frequently Asked Questions
What is the deal between Enveric and MindBio?
Enveric has signed a non-binding term sheet to out-license psilocin prodrugs to MindBio.
What is MindBio Therapeutics known for?
MindBio Therapeutics specializes in developing treatments for psychiatric conditions using psychedelics.
What type of medicines are involved in this partnership?
The partnership focuses on novel psilocin prodrugs intended for psychiatric treatments.
Is the agreement between Enveric and MindBio binding?
The agreement is currently a non-binding term sheet.